DaVita (DVA) Q2 2025 Earnings Call August 05, 2025 05:00 PM ET Speaker0Evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita Second Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period.Thank you, Mr. Lysen. You may begin your conference.Speaker1Thank you, and welcome to our second quarter confere ...

Captures key initiatives achieved in 2024, driving 2025 ESG goalsDENVER, May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024.In 2021, DaVita announced broadened ESG goals and has since reported progress against its five str ...

Core Viewpoint - DaVita Inc. has initiated a private offering of $750 million in senior notes due 2033 to manage its financial obligations and support corporate activities [1][2]. Group 1: Offering Details - The offering consists of $750 million aggregate principal amount of senior notes due in 2033 [1]. - The net proceeds from the offering will be used to repay outstanding revolving credit facility borrowings, cover related costs, and for general corporate purposes, including stock repurchases and capital expenditures [2]. Group 2: Regulatory Compliance - The 2033 notes are being offered only to qualified institutional buyers under Rule 144A and to certain non-U.S. persons in compliance with Regulation S [3]. - The offer and sale of the 2033 notes have not been registered under the Securities Act and cannot be sold in the U.S. without registration or an exemption [3][4]. Group 3: Company Overview - DaVita is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients globally, particularly in kidney care [5]. - The company has been a leader in clinical quality and innovation for 25 years, providing care at every stage of kidney health [5].